Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
About this item
Full title
Author / Creator
Slamon, Dennis , Eiermann, Wolfgang , Robert, Nicholas , Pienkowski, Tadeusz , Martin, Miguel , Press, Michael , Mackey, John , Glaspy, John , Chan, Arlene , Pawlicki, Marek , Pinter, Tamas , Valero, Vicente , Liu, Mei-Ching , Sauter, Guido , von Minckwitz, Gunter , Visco, Frances , Bee, Valerie , Buyse, Marc , Bendahmane, Belguendouz , Tabah-Fisch, Isabelle , Lindsay, Mary-Ann , Riva, Alessandro , Crown, John and Breast Cancer International Research Group
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Trastuzumab added to a nonanthracycline regimen to treat HER2-positive breast cancer resulted in rates of disease-free and overall survival that were similar to those for an anthracycline-containing regimen, with lower rates of cardiac toxicity and secondary leukemia.
The HER2 gene encodes a tyrosine kinase receptor that mediates critical signal...
Alternative Titles
Full title
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Authors, Artists and Contributors
Author / Creator
Eiermann, Wolfgang
Robert, Nicholas
Pienkowski, Tadeusz
Martin, Miguel
Press, Michael
Mackey, John
Glaspy, John
Chan, Arlene
Pawlicki, Marek
Pinter, Tamas
Valero, Vicente
Liu, Mei-Ching
Sauter, Guido
von Minckwitz, Gunter
Visco, Frances
Bee, Valerie
Buyse, Marc
Bendahmane, Belguendouz
Tabah-Fisch, Isabelle
Lindsay, Mary-Ann
Riva, Alessandro
Crown, John
Breast Cancer International Research Group
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3268553
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3268553
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa0910383
